Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,666 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, Matsumoto A, Yamaguchi K, Isobe Y, Tsuchiya A, Shikata S, Sato N, Morinaga H, Fukuyama T, Tanaka Y, Fukushima T, Takeda R, Yamamoto K, Honda H, Nishimura EK, Furukawa Y, Shibata T, Abdel-Wahab O, Suematsu M, Kitamura T. Fujino T, et al. Among authors: yamasaki s. Nat Commun. 2021 Mar 23;12(1):1826. doi: 10.1038/s41467-021-22053-y. Nat Commun. 2021. PMID: 33758188 Free PMC article.
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi Y, Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, Fukuyama T, Wunderlich M, O'Brien E, Mizukawa B, Yamazaki S, Matsumoto A, Yamasaki S, Shibata T, Matsuda K, Sashida G, Takizawa H, Kitamura T. Hayashi Y, et al. Among authors: yamasaki s. Nat Commun. 2019 Oct 25;10(1):4869. doi: 10.1038/s41467-019-12555-1. Nat Commun. 2019. PMID: 31653912 Free PMC article.
HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
Takeda R, Asada S, Park SJ, Yokoyama A, Becker HJ, Kanai A, Visconte V, Hershberger C, Hayashi Y, Yonezawa T, Tamura M, Fukushima T, Tanaka Y, Fukuyama T, Matsumoto A, Yamasaki S, Nakai K, Yamazaki S, Inaba T, Shibata T, Inoue D, Honda H, Goyama S, Maciejewski JP, Kitamura T. Takeda R, et al. Among authors: yamasaki s. Blood. 2020 Oct 1;136(14):1670-1684. doi: 10.1182/blood.2019004613. Blood. 2020. PMID: 32492700 Free article.
Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Heike Y, Tobinai K, Tanosaki R, Takaue Y. Fuji S, et al. Among authors: yamasaki s. Biol Blood Marrow Transplant. 2008 May;14(5):510-7. doi: 10.1016/j.bbmt.2008.02.008. Biol Blood Marrow Transplant. 2008. PMID: 18410893 Free article.
Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation.
Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Honda O, Kuwahara S, Tanosaki R, Heike Y, Tobinai K, Takaue Y. Fuji S, et al. Among authors: yamasaki s. Transplantation. 2007 Oct 15;84(7):814-20. doi: 10.1097/01.tp.0000296482.50994.1c. Transplantation. 2007. PMID: 17984832
Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens.
Yamasaki S, Miyagi-Maeshima A, Kakugawa Y, Matsuno Y, Ohara-Waki F, Fuji S, Morita-Hoshi Y, Mori M, Kim SW, Mori S, Fukuda T, Tanosaki R, Shimoda T, Tobinai K, Saito D, Takaue Y, Teshima T, Heike Y. Yamasaki S, et al. Int J Hematol. 2013 Mar;97(3):421-6. doi: 10.1007/s12185-013-1297-9. Epub 2013 Feb 23. Int J Hematol. 2013. PMID: 23435651 Clinical Trial.
Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.
Kuno M, Yamasaki S, Fujii N, Ishida Y, Fukuda T, Kataoka K, Uchida N, Katayama Y, Sato M, Onai D, Miyamoto T, Ota S, Yoshioka S, Ara T, Hangaishi A, Hashii Y, Onizuka M, Ichinohe T, Atsuta Y, Inamoto Y; on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group. Kuno M, et al. Among authors: yamasaki s. Am J Hematol. 2022 Feb 1;97(2):185-193. doi: 10.1002/ajh.26401. Epub 2021 Nov 16. Am J Hematol. 2022. PMID: 34738245 Free article.
Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.
Aoki J, Kanamori H, Tanaka M, Yamasaki S, Fukuda T, Ogawa H, Iwato K, Ohashi K, Okumura H, Onizuka M, Maesako Y, Teshima T, Kobayashi N, Morishima Y, Hirokawa M, Atsuta Y, Yano S, Takami A. Aoki J, et al. Among authors: yamasaki s. Am J Hematol. 2016 Mar;91(3):302-7. doi: 10.1002/ajh.24270. Epub 2016 Jan 11. Am J Hematol. 2016. PMID: 26663096 Free article.
Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K, Yamasaki S, Inoue Y, Moriuchi Y, Choi I, Ogata M, Hidaka M, Yamaguchi T, Fukuda T. Fuji S, et al. Among authors: yamasaki s. Bone Marrow Transplant. 2018 Jul;53(7):905-908. doi: 10.1038/s41409-017-0082-4. Epub 2018 Jan 25. Bone Marrow Transplant. 2018. PMID: 29371687 No abstract available.
1,666 results